Dendritic cell (DC) based therapy for cervical cancer

Use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C12U] (Ampligen®)

M. Adams, H. Navabi, B. Jasani, S. Man, A. Fiander, A. S. Evans, C. Donninger, M. Mason

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Human papilloma virus (HPV) found in 99.7% of cervical cancers represents an attractive immunotherapeutic target for novel adjuvant dendritic cell (DC) immunotherapy. DC primed with HPV antigens have been shown to be capable of inducing CTL responses powerful enough to eradicate established murine tumours expressing HPV16 antigen. The use of tumour lysate has been found to be an effective means of priming DC with tumour associated antigens in animal models and in clinical trials leading to significant anti-tumour responses. Autologous DC primed with sonicated HPV expressing tumour lysate have been shown to be capable of inducing HPV specific classes I and II T-cell immunity in a pilot clinical study. Synthetic double stranded polyribonucleotides are effective in vitro activation/maturation agents capable of inducing a stable mature DC phenotype producing high levels of IL12. However, the prototype polymer poly [I]:poly [G] has proved to be clinically toxic. Preliminary in vitro data have demonstrated that a novel clinically non-toxic analogue polymer poly [I]:poly [C12U] (Ampligen®) can effectively induce in vitro maturation of human monocyte derived DC with sustained bioactive IL12 production. Human monocyte derived DC primed with tumour lysate and matured with synthetic dsRNA may therefore offer an effective way of optimising Th1 specific anti-cancer T-cell responses in cancer patients. This strategy is currently being tested in a clinical trial in patients with cervical cancer.

Original languageEnglish
Pages (from-to)787-790
Number of pages4
JournalVaccine
Volume21
Issue number7-8
DOIs
Publication statusPublished - Jan 30 2003
Externally publishedYes

Fingerprint

uterine cervical neoplasms
Double-Stranded RNA
Papillomaviridae
double-stranded RNA
dendritic cells
Cell- and Tissue-Based Therapy
Uterine Cervical Neoplasms
Dendritic Cells
papilloma
therapeutics
neoplasms
Neoplasms
clinical trials
viruses
Interleukin-12
antigens
monocytes
Monocytes
polymers
Polymers

Keywords

  • Cervical cancer
  • Dendritic cell
  • Polyriboinosinic:polyribocytidylic acid analogues (poly [I]:poly [C] and poly [I]:poly [CU])

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Dendritic cell (DC) based therapy for cervical cancer : Use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C12U] (Ampligen®). / Adams, M.; Navabi, H.; Jasani, B.; Man, S.; Fiander, A.; Evans, A. S.; Donninger, C.; Mason, M.

In: Vaccine, Vol. 21, No. 7-8, 30.01.2003, p. 787-790.

Research output: Contribution to journalArticle

Adams, M. ; Navabi, H. ; Jasani, B. ; Man, S. ; Fiander, A. ; Evans, A. S. ; Donninger, C. ; Mason, M. / Dendritic cell (DC) based therapy for cervical cancer : Use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C12U] (Ampligen®). In: Vaccine. 2003 ; Vol. 21, No. 7-8. pp. 787-790.
@article{84d57792e08148169f06dce8083287c4,
title = "Dendritic cell (DC) based therapy for cervical cancer: Use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C12U] (Ampligen{\circledR})",
abstract = "Human papilloma virus (HPV) found in 99.7{\%} of cervical cancers represents an attractive immunotherapeutic target for novel adjuvant dendritic cell (DC) immunotherapy. DC primed with HPV antigens have been shown to be capable of inducing CTL responses powerful enough to eradicate established murine tumours expressing HPV16 antigen. The use of tumour lysate has been found to be an effective means of priming DC with tumour associated antigens in animal models and in clinical trials leading to significant anti-tumour responses. Autologous DC primed with sonicated HPV expressing tumour lysate have been shown to be capable of inducing HPV specific classes I and II T-cell immunity in a pilot clinical study. Synthetic double stranded polyribonucleotides are effective in vitro activation/maturation agents capable of inducing a stable mature DC phenotype producing high levels of IL12. However, the prototype polymer poly [I]:poly [G] has proved to be clinically toxic. Preliminary in vitro data have demonstrated that a novel clinically non-toxic analogue polymer poly [I]:poly [C12U] (Ampligen{\circledR}) can effectively induce in vitro maturation of human monocyte derived DC with sustained bioactive IL12 production. Human monocyte derived DC primed with tumour lysate and matured with synthetic dsRNA may therefore offer an effective way of optimising Th1 specific anti-cancer T-cell responses in cancer patients. This strategy is currently being tested in a clinical trial in patients with cervical cancer.",
keywords = "Cervical cancer, Dendritic cell, Polyriboinosinic:polyribocytidylic acid analogues (poly [I]:poly [C] and poly [I]:poly [CU])",
author = "M. Adams and H. Navabi and B. Jasani and S. Man and A. Fiander and Evans, {A. S.} and C. Donninger and M. Mason",
year = "2003",
month = "1",
day = "30",
doi = "10.1016/S0264-410X(02)00599-6",
language = "English",
volume = "21",
pages = "787--790",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "7-8",

}

TY - JOUR

T1 - Dendritic cell (DC) based therapy for cervical cancer

T2 - Use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C12U] (Ampligen®)

AU - Adams, M.

AU - Navabi, H.

AU - Jasani, B.

AU - Man, S.

AU - Fiander, A.

AU - Evans, A. S.

AU - Donninger, C.

AU - Mason, M.

PY - 2003/1/30

Y1 - 2003/1/30

N2 - Human papilloma virus (HPV) found in 99.7% of cervical cancers represents an attractive immunotherapeutic target for novel adjuvant dendritic cell (DC) immunotherapy. DC primed with HPV antigens have been shown to be capable of inducing CTL responses powerful enough to eradicate established murine tumours expressing HPV16 antigen. The use of tumour lysate has been found to be an effective means of priming DC with tumour associated antigens in animal models and in clinical trials leading to significant anti-tumour responses. Autologous DC primed with sonicated HPV expressing tumour lysate have been shown to be capable of inducing HPV specific classes I and II T-cell immunity in a pilot clinical study. Synthetic double stranded polyribonucleotides are effective in vitro activation/maturation agents capable of inducing a stable mature DC phenotype producing high levels of IL12. However, the prototype polymer poly [I]:poly [G] has proved to be clinically toxic. Preliminary in vitro data have demonstrated that a novel clinically non-toxic analogue polymer poly [I]:poly [C12U] (Ampligen®) can effectively induce in vitro maturation of human monocyte derived DC with sustained bioactive IL12 production. Human monocyte derived DC primed with tumour lysate and matured with synthetic dsRNA may therefore offer an effective way of optimising Th1 specific anti-cancer T-cell responses in cancer patients. This strategy is currently being tested in a clinical trial in patients with cervical cancer.

AB - Human papilloma virus (HPV) found in 99.7% of cervical cancers represents an attractive immunotherapeutic target for novel adjuvant dendritic cell (DC) immunotherapy. DC primed with HPV antigens have been shown to be capable of inducing CTL responses powerful enough to eradicate established murine tumours expressing HPV16 antigen. The use of tumour lysate has been found to be an effective means of priming DC with tumour associated antigens in animal models and in clinical trials leading to significant anti-tumour responses. Autologous DC primed with sonicated HPV expressing tumour lysate have been shown to be capable of inducing HPV specific classes I and II T-cell immunity in a pilot clinical study. Synthetic double stranded polyribonucleotides are effective in vitro activation/maturation agents capable of inducing a stable mature DC phenotype producing high levels of IL12. However, the prototype polymer poly [I]:poly [G] has proved to be clinically toxic. Preliminary in vitro data have demonstrated that a novel clinically non-toxic analogue polymer poly [I]:poly [C12U] (Ampligen®) can effectively induce in vitro maturation of human monocyte derived DC with sustained bioactive IL12 production. Human monocyte derived DC primed with tumour lysate and matured with synthetic dsRNA may therefore offer an effective way of optimising Th1 specific anti-cancer T-cell responses in cancer patients. This strategy is currently being tested in a clinical trial in patients with cervical cancer.

KW - Cervical cancer

KW - Dendritic cell

KW - Polyriboinosinic:polyribocytidylic acid analogues (poly [I]:poly [C] and poly [I]:poly [CU])

UR - http://www.scopus.com/inward/record.url?scp=0037472447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037472447&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(02)00599-6

DO - 10.1016/S0264-410X(02)00599-6

M3 - Article

VL - 21

SP - 787

EP - 790

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 7-8

ER -